Natco Pharma, a Rs.960 crore pharma major from Hyderabad, has registered impressive financial performance during the first quarter ended June 2016 due to higher sales of its oncology and hepatitis C products in India. Its net profit has taken a quantum jump of 69.8 per cent to Rs.47.65 crore from Rs.28.07 crore in the corresponding period of last year. EBDITA also increased by 39.4 per cent to Rs.82.41 crore from Rs.59.13 crore. EPS worked out to Rs.2.74 as against Rs.1.70 in the last period. The company's equity shares with face value of Rs.10 per share were sub-divided into 5 equity shares of Rs.2 each effective from November 30, 2015. The company management recommended interim equity dividend of 37.5 per cent.
Its net sales moved up by 38 per cent to Rs.297.71 crore from Rs.215.69 crore mainly due to higher sales of formulations by 65.7 per cent to Rs.283.57 crore from Rs.171.12 crore. Its sales of bulk chemicals increased marginally by 2 per cent to Rs.56.96 crore from Rs.55.80 crore.
The company reduced its interest cost by over 60 per cent to Rs.3.20 crore from Rs.8.08 crore. Its other operating income increased to Rs.27.51 crore from Rs.8.02 crore and other to Rs.5.16 crore from Rs.1.83 crore in the similar quarter of last year. However, its tax provision went up to Rs.18.63 crore from Rs.11.03 crore.